SOL S.p.A. — Cyborg Score 7/10

Strong
Specialty Chemicals / Industrial Gases

Strategic Profile

As an Italy-based company primarily engaged in the research, production and distribution of industrial, pure and medicinal gases with significant involvement in the home care medical business through provision of home care services such as oxygen therapy, mechanical ventilation, and diagnosis and care of obstructive sleep apnea syndrome, SOL has established a diversified healthcare-industrial hybrid model. The company leverages digital health solutions including InfoHealth SOLution, a web platform that controls plans, coordinates, and manages all activities carried out within healthcare facilities, positioning it competitively in both traditional industrial gases and modern healthcare services.

Cyborg Score Rationale

SOL demonstrates strong fundamentals with 2024 revenue of €1.64 billion, an increase of 7.53% compared to 2023, and a diversified business model spanning industrial gases and home healthcare services. The company benefits from demographic tailwinds in aging European populations and healthcare digitization trends, supported by its proprietary InfoHealth platform. However, exposure to mature European markets and commodity-driven gas segments may limit growth acceleration.

Top Insights

  • Dual revenue model provides resilience: home care segment (majority revenue, recurring) balanced with technical gases (cyclical but higher margins)
  • Digital health platform (InfoHealth SOLution) differentiates from pure gas competitors and captures healthcare modernization trends
  • 7,291 employees across global operations with strong Italian market presence (2024 revenue €1.64B)
  • Healthcare services expansion through subsidiaries addresses high-margin, recurring home care market with aging population tailwinds

Named Competitors

  • Linde — Global industrial gases and engineering leader
  • Air Liquide — Worldwide supplier of gases and chemical services
  • Messer — European industrial gases specialist

Recent Developments

  • (February 2026) Company remains operationally stable with recent analyst coverage establishing price target of EUR 54.50 at Hold rating
  • (2024) Revenue growth of 7.53% year-over-year to €1.64 billion with expanding profitability
  • (2024) Continued expansion of home care services and medical devices portfolio serving underserved geographies

Open the full interactive SOL S.p.A. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →